skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Treatment planning for internal emitter therapy: Methods, applications and clinical implications

Abstract

Treatment planning involves three basic steps: (1) a procedure must be devised that will provide the most relevant information, (2) the procedure must be applied and (3) the resulting information must be translated into a definition of the optimum implementation. There are varying degrees of treatment planning that may be implemented in internal emitter therapy. As in chemotherapy, the information from a Phase 1 study may be used to treat patients based upon body surface area. If treatment planning is included on a patient-specific basis, a pretherapy, trace-labeled, administration of the radiopharmaceutical is generally required. The data collected following the tracer dose may range from time-activity curves of blood and whole-body for use in blood, marrow or total body absorbed dose estimation to patient imaging for three-dimensional internal emitter dosimetry. The most ambitious approach requires a three-dimensional set of images representing radionuclide distribution (SPECT or PET) and a corresponding set of images representing anatomy (CT or MRI). The absorbed dose (or dose-rate) distribution may be obtained by convolution of a point kernel with the radioactivity distribution or by direct Monte Carlo calculation. A critical requirement for both techniques is the development of an overall structure that makes it possible, inmore » a routine manner, to input the images, to identify the structures of interest and to display the results of the dose calculations in a clinically relevant manner. 52 refs., 4 figs., 1 tab.« less

Authors:
 [1]
  1. Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
Publication Date:
Research Org.:
Oak Ridge Associated Universities, TN (United States)
Sponsoring Org.:
National Insts. of Health, Bethesda, MD (United States); USDOE, Washington, DC (United States)
OSTI Identifier:
684481
Report Number(s):
ORISE-99-0164-Vol.1; CONF-960536-PROC.-Vol.1
ON: DE99002903; TRN: IM9943%%172
DOE Contract Number:  
FG02-86ER60407
Resource Type:
Conference
Resource Relation:
Conference: 6. international radiopharmaceutical dosimetry symposium, Gatlinburg, TN (United States), 7-10 May 1996; Other Information: PBD: Jan 1999; Related Information: Is Part Of Sixth international radiopharmaceutical dosimetry symposium: Proceedings. Volume 1; S.-Stelson, A.T. [ed.] [comp.]; Stabin, M.G.; Sparks, R.B. [eds.]; Smith, F.B. [comp.]; PB: 386 p.
Country of Publication:
United States
Language:
English
Subject:
56 BIOLOGY AND MEDICINE, APPLIED STUDIES; 55 BIOLOGY AND MEDICINE, BASIC STUDIES; RADIOTHERAPY; DOSIMETRY; RADIATION DOSES; PLANNING; RADIATION DOSE DISTRIBUTIONS

Citation Formats

Sgouros, G. Treatment planning for internal emitter therapy: Methods, applications and clinical implications. United States: N. p., 1999. Web.
Sgouros, G. Treatment planning for internal emitter therapy: Methods, applications and clinical implications. United States.
Sgouros, G. 1999. "Treatment planning for internal emitter therapy: Methods, applications and clinical implications". United States. https://www.osti.gov/servlets/purl/684481.
@article{osti_684481,
title = {Treatment planning for internal emitter therapy: Methods, applications and clinical implications},
author = {Sgouros, G},
abstractNote = {Treatment planning involves three basic steps: (1) a procedure must be devised that will provide the most relevant information, (2) the procedure must be applied and (3) the resulting information must be translated into a definition of the optimum implementation. There are varying degrees of treatment planning that may be implemented in internal emitter therapy. As in chemotherapy, the information from a Phase 1 study may be used to treat patients based upon body surface area. If treatment planning is included on a patient-specific basis, a pretherapy, trace-labeled, administration of the radiopharmaceutical is generally required. The data collected following the tracer dose may range from time-activity curves of blood and whole-body for use in blood, marrow or total body absorbed dose estimation to patient imaging for three-dimensional internal emitter dosimetry. The most ambitious approach requires a three-dimensional set of images representing radionuclide distribution (SPECT or PET) and a corresponding set of images representing anatomy (CT or MRI). The absorbed dose (or dose-rate) distribution may be obtained by convolution of a point kernel with the radioactivity distribution or by direct Monte Carlo calculation. A critical requirement for both techniques is the development of an overall structure that makes it possible, in a routine manner, to input the images, to identify the structures of interest and to display the results of the dose calculations in a clinically relevant manner. 52 refs., 4 figs., 1 tab.},
doi = {},
url = {https://www.osti.gov/biblio/684481}, journal = {},
number = ,
volume = ,
place = {United States},
year = {Fri Jan 01 00:00:00 EST 1999},
month = {Fri Jan 01 00:00:00 EST 1999}
}

Conference:
Other availability
Please see Document Availability for additional information on obtaining the full-text document. Library patrons may search WorldCat to identify libraries that hold this conference proceeding.

Save / Share: